These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 8490108

  • 1. Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations.
    Kiriyama A, Mimoto T, Kiso Y, Takada K.
    Biopharm Drug Dispos; 1993 Apr; 14(3):199-207. PubMed ID: 8490108
    [Abstract] [Full Text] [Related]

  • 2. Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations.
    Kiriyama A, Mimoto T, Kisanuki S, Kiso Y, Takada K.
    Biopharm Drug Dispos; 1993 Nov; 14(8):697-707. PubMed ID: 8305629
    [Abstract] [Full Text] [Related]

  • 3. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration.
    Kiriyama A, Fujita K, Takemura S, Kuramoto H, Kiso Y, Takada K.
    Biopharm Drug Dispos; 1994 Oct; 15(7):617-26. PubMed ID: 7849237
    [Abstract] [Full Text] [Related]

  • 4. Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: effect of solvent.
    Sugahara M, Kiriyama A, Hamada Y, Kiso Y, Takada K.
    Biopharm Drug Dispos; 1995 May; 16(4):269-77. PubMed ID: 7548776
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes.
    Kiriyama A, Nishiura T, Yamaji H, Takada K.
    Antimicrob Agents Chemother; 1999 Mar; 43(3):549-56. PubMed ID: 10049266
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S, Kang LW, Velazquez-Campoy A, Kiso Y, Amzel LM, Freire E.
    Proteins; 2004 May 15; 55(3):594-602. PubMed ID: 15103623
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.
    Chokekijchai S, Shirasaka T, Weinstein JN, Mitsuya H.
    Antiviral Res; 1995 Sep 15; 28(1):25-38. PubMed ID: 8585758
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of pidotimod in rats and dogs.
    Coppi G, Silingardi S.
    Arzneimittelforschung; 1994 Dec 15; 44(12A):1460-4. PubMed ID: 7857342
    [Abstract] [Full Text] [Related]

  • 16. A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs.
    Wong YN, Burcham DL, Saxton PL, Erickson-Viitanen S, Grubb MF, Quon CY, Huang SM.
    Biopharm Drug Dispos; 1994 Oct 15; 15(7):535-44. PubMed ID: 7849230
    [Abstract] [Full Text] [Related]

  • 17. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
    Kiriyama A, Nishiura T, Ishino M, Yamamoto Y, Ogita I, Kiso Y, Takada K.
    Biopharm Drug Dispos; 1996 Dec 15; 17(9):739-51. PubMed ID: 8968527
    [Abstract] [Full Text] [Related]

  • 18. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease.
    Shetty BV, Kosa MB, Khalil DA, Webber S.
    Antimicrob Agents Chemother; 1996 Jan 15; 40(1):110-4. PubMed ID: 8787890
    [Abstract] [Full Text] [Related]

  • 19. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T, Kato R, Takaku H, Nojima S, Terashima K, Misawa S, Fukazawa T, Ueno T, Sato H, Shintani M, Kiso Y, Hayashi H.
    J Med Chem; 1999 May 20; 42(10):1789-802. PubMed ID: 10346931
    [Abstract] [Full Text] [Related]

  • 20. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.
    Mimoto T, Imai J, Kisanuki S, Enomoto H, Hattori N, Akaji K, Kiso Y.
    Chem Pharm Bull (Tokyo); 1992 Aug 20; 40(8):2251-3. PubMed ID: 1423795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.